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ABSTRACT
Background. Breast-conserving therapy (BCT) and mas-
tectomy (MTX) has been considered to have a similar long-
time survival. However, better survival in women under-
going BCT compared with MTX is found in two recent
register studies from the United States. The purpose of this
study was to compare survival after BCT and MTX for
women with early-stage breast cancer in Norway.
Methods. Women with invasive, early-stage breast cancer
(1998–2008) where BCT and MTX were considered as
equally beneficial treatments were included for a total of
13,015 women. Surgery was divided in two main cohorts
(primary BCT, primary MTX) and five subcohorts. Ana-
lyses were stratified into T1N0M0, T2N0M0, T1N1M0,
T2N1M0, and age groups (\50, 50–69, C70). Overall
survival and breast cancer-specific survival (BCSS) were
calculated in life tables, hazard ratios by Cox regression,
and sensitivity analyses.
Results. Five-year BCSS for women who underwent pri-
mary BCT or primary MTX was 97 and 88 %, respectively.
Women who underwent primary MTX had a hazard ratio
of 1.64 (95 % confidence interval 1.43–1.88) for breast
cancer death compared with women who underwent pri-
mary BCT after adjusting for the year of diagnosis, age at
diagnosis, stage, histology, and grade.
Conclusions. Survival was better or equal after breast-
conserving therapy than mastectomy in all early stages,
surgical subcohorts, and age groups. This advantage could
not only be attributed to differences in tumor biology.
INTRODUCTION
The clinical trials comparing breast-conserving therapy
(BCT) with mastectomy (MTX) were done decades ago.1–6
Since these studies were conducted, treatment and especially
adjuvant therapy have changed and survival improved.7,8
In 2013, Hwang et al. published a paper reporting better
survival among patients undergoing BCT compared with
MTX, challenging the notion of equality in survival be-
tween BCT and MTX.9 They suggested that differences in
tumor biology might have contributed to survival differ-
ences between BCT and MTX. In January 2014, Agarwal
et al. published a paper corroborating the results of
Hwang.10 They assumed that a difference in the breast
cancer-specific survival rate between BCT and MTX might
be due to differences in compliance to adjuvant therapy or
tumor biology. Because these two studies were not ran-
domized trials but observational studies, more studies on
this topic are needed, especially outside the United States.
In Norway, all cancer cases have to be reported to the
Cancer Registry of Norway, making this a complete reg-
ister for the whole population of Norway with the
possibility to form a cohort where, according to national
guidelines, BCT and MTX are considered as equal treat-
ment options.11 The purpose of this study was to compare
differences in survival after BCT and MTX for women
with early-stage breast cancer in Norway.
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MATERIALS AND METHODS
In this study, data from the Cancer Registry of Norway
containing information on diagnosis, time of diagnosis,
surgery type, surgery month, morphology, tumor grade,
and TNM classification (done according to Union of
International Cancer Control) were used.12
Cohort Selection
A total of 27,182 female residents of Norway were
diagnosed with invasive, primary, early-stage breast cancer
during the period January 1, 1998 to December 31, 2008. In
this study, early-stage breast cancer is defined as T1–2
N0–1 M0 and stratified into T1N0M0, T2N0M0, T1N1M0,
and T2N1M0 (tumor size B 5 cm and 0–3 ipsilateral
axillary nodes with metastasis). From these women, a
cohort who, according to the Norwegian Breast Cancer
Group (NBCG) recommendations, could be offered either
MTX or BCT was selected.7
The women excluded were as follows: women with
previous cancer (2501), women diagnosed with more than
one primary breast cancer in same or contralateral breast
within 3 months (840), women who did not undergo sur-
gery or information about the operation was missing (2153
of these 41 % were aged C 80 years), missing information
about metastasis status (4919 of these 35 % underwent
BCT as primary and 65 % underwent MTX as primary),
unknown size of tumor or unknown nodal status (2196),
final BCT (BCT operated once and BCT with reoperation)
not received or missing information on RT (1073), final
BCT receiving RT more than 365 days after diagnosis (62),
women who received radiotherapy after MTX when nodal
axillary status was negative (399), and women who died
within 3 months after primary operation (24). The final
cohort consists of 13,015 women.
Surgical Cohorts
Surgery was divided into two main cohorts: primary
BCT and primary MTX. Primary BCT was further divided
into three subcohorts: BCT operated once, BCT with re-
operation, and BCT followed by MTX. Primary MTX was
divided into two subcohorts: MTX operated once and MTX
with reoperation. Division of surgical main and subcohorts
was done 3 months after primary operation. If no further
operation was done 3 months after primary operation, the
operation was defined as one operation (BCT operated
once and MTX operated once). If the women underwent
two or more surgeries within 3 months after primary the
operation, the operation was defined as several (BCT with
reoperation, BCT followed by MTX, and MTX with
reoperation).
Treatment Recommendations from the Norwegian
Breast Cancer Group Between 1998 and 2008
NBCG criteria to accept BCT as final result of surgery
was as follows: free margin should be at least 5 mm from
1998 to 2003 and 3 mm from 2003 to 2008; an acceptable
cosmetic result obtained; tumor size\ 5 cm from 2003;
multifocal tumors were not accepted from 1998 to 2003;
multifocal tumors\ 1 cm apart were accepted for BCT
from 2003.
Radiation therapy: all women undergoing BCT as final
treatment should receive RT. Women younger than
55 years undergoing MTX with one to three positive nodes
in axilla were recommended RT to chest wall and axilla
from year 1998 to 2003; the age was increased to 70 years
from 2003. Women undergoing MTX also were recom-
mended RT if margins were not free. Radiation therapy
was deemed given if the patient received a total dose of
47 Gy or more and start of treatment was no more than
365 days from date of diagnosis.
Neoadjuvant treatment is not recommended for early-
stage breast cancer. Furthermore, choice of surgery did not
influence recommendations of adjuvant chemotherapy or
antiestrogen therapy.
Statistical Analyses
Life tables for 5-year overall survival (OS) and breast
cancer-specific survival (BCSS) were stratified by primary
BCT, primary MTX, and the following age groups:
\50 years, 50–69 years, and C70 years. Furthermore, the
surgical main cohorts were stratified in grade 1–3, ductal
carcinoma, T1N0M0, T2N0M0, T1N1M0, T2N1M0,
age\ 50, age 50–69, and age C 70 years. Kaplan–Meier
curves were stratified in T1N1M0, grade 3, ductal carci-
noma, and age 50–69 years in the surgical main and sub
cohorts.
Cox proportional hazards were performed to estimate
crude and adjusted hazard ratios for OS and BCSS between
BCT and MTX in the surgical main and subcohorts. Cox
analyses were performed in the following strata: surgical
main cohorts; surgical sub cohorts; first 3 and last 3 years
of the study period; women aged\ 50 years; women aged
50–69 years; women aged C 70 years; T1N0M0 grade1;
T1-2N1M0 where primary MTX received RT and T1-
2N1M0 where primary MTX did not receive RT. Fur-
thermore, multivariate analysis was performed were all
women receiving RT after MTX were excluded from the
cohort. The multivariate analysis was adjusted in the sur-
gical subcohorts for the year of diagnosis, stage, age,
histology, and grade. Deterministic sensitivity analyses
were performed on misclassification of surgery, selection
bias, and uncontrolled confounding according to
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Greenland.13 Statistical analyses were conducted in
STATA version 13.1 (StataCorp, Texas, USA).
RESULTS
Of the 13,015 women with early-stage breast cancer,
8065 (62 %) underwent primary BCT and 4950 (38 %)
underwent primary MTX. Table 1 shows clinical charac-
teristics of the patient cohort.
RT was given to 99.3 % in primary BCT and 30.7 % in
primary MTX. In the subcohorts, RT was given to 100 %
in BCT operated once, 100 % in BCT with reoperation,
70 % in BCT followed by MTX, 30 % in MTX operated
once, and 43 % in MTX with reoperation. The proportion
of women who underwent primary BCT is highest among
women aged 50–69 years. Of women aged 70–79 years,
62 % were operated with primary MTX. At age 80 years
and older, 88 % were operated with primary MTX.
Impact of Surgery Type on Overall and Breast
Cancer-Specific Survival
A total of 2,475 deaths were identified in the cohort
during the study period, including 1,132 (1,083 after
10 years) due to breast cancer. The 5-year OS was 89 %,
and BCSS was 94 % (Table 2). Life tables showed better
survival for women undergoing BCT compared with MTX.
For women who underwent primary BCT or primary MTX,
the 5-year BCSS was 97 and 88 %, respectively. In the age
group 50–69 years, the 5-year BCSS for those who un-
derwent primary BCT was 98 and 90 %, respectively.
The main and surgical subcohorts stratified in stage
T1N1M0, grade 3, and ductal carcinoma showed better
survival among women undergoing BCT compared with
MTX (Kaplan–Meier curves in Fig. 1)
Furthermore, the two main surgical cohorts, primary BCT
and primary MTX, were stratified in grade 1–3, ductal car-
cinoma, and stage (T1N0M0, T2N0M0, T1N1M0,
T2N1M0), and none of these strata showed a significant
benefit of MTX over BCT; i.e., in all these analyses, BCT
was better or equal compared with MTX regarding survival
(result not shown in table). Women who underwent MTX
with reoperation had the worst prognosis, 79 % 5-year BCSS
(Table 2).
In the adjusted Cox analysis, women who underwent
primary MTX had a hazard ratio [HR] of 1.64 (95 %
confidence interval [CI] 1.43–1.88) for breast cancer death
compared with women who underwent primary BCT
(Table 3). Adjusted analysis in the beginning of study pe-
riod (1998–2001) showed HR 1.76 (95 % CI 1.02–3.05)
compared with the end of study period (2006–2008) with
HR 1.88 (95 % CI 1.23–2.87). Results not shown in table.
Women younger than 50 years who underwent primary
MTX had HR 1.58 (95 % CI 1.22–2.04) for breast cancer
death compared with women who underwent primary BCT
(Table 4). A stratified adjusted analysis performed for
women aged 50–69 years (screening age) who underwent
primary MTX showed an HR of 1.64 (95 % CI 1.35–1.99)
for breast cancer death compared with women who un-
derwent primary BCT with base HR 1.00.
Women not recommended to receive chemotherapy or
antiestrogen therapy, i.e., T1N0M0 grade 1, who under-
went primary MTX had an HR of 2.07 (95 % CI 0.94–
6.61) compared with women who underwent primary BCT.
Women with node-positive disease (T1-2N1M0) where
all in the primary MTX strata received RT gave a primary
MTX HR of 2.13 (95 % CI 1.52–2.98) compared with
primary BCT with base HR 1.00 (result not shown in
table). Respectively, women with node-positive disease
(T1-2N1M0) where no one in the primary MTX received
RT gave a primary MTX HR of 2.16 (95 % CI 1.78–2.61)
compared with primary BCT with base HR 1.00 (result not
shown in table). MTX stage T1-2N1M0 shows no advan-
tage of receiving RT. Multivariate analysis where all
women receiving RT after MTX were excluded (1,521
women) gave a primary MTX HR of 1.51 (95 % CI
1.27–1.80) compared with primary BCT with base HR 1.00
(result not shown in table).
Women operated with BCT followed by MTX were
found to have a worse prognosis compared with women
who underwent BCT operated once, BCT with reoperation,
and MTX operated once in the adjusted analysis. Never-
theless, only 0.7 % of the primary BCT cohort underwent
BCT followed by MTX without receiving RT.
After MTX, 164 underwent reoperation. This group had
the worst prognosis in the cohort; 34 % (55) died of breast
cancer during a median follow-up time of 6.9 years.
Sensitivity Analyses
When assuming a dichotomous unmeasured confounder
to present in 20, 40, 60, and 90 % of the women under-
going MTX, and 10 % in among women undergoing BCT,
the rate ratios were of 2.57, 1.78, 1.36, and 1.01, respec-
tively. In these analyses, we assumed the relative risk of
confounding to be 5. Sensitivity analyses of misclassifica-
tion of surgery and selection bias did not show lower risk
between MTX and BCT than in the crude analysis.
DISCUSSION
The main finding of this study is that both OS and BCSS
were better in women with early-stage breast cancer un-
dergoing BCT compared with MTX. This is contrary to the
3838 O. J. Hartmann-Johnsen et al.
TABLE 1 Baseline characteristics
Surgical main cohorts Surgical sub cohorts
Number 13,015 Reoperateda Number 13,015
PrimaryBCT PrimaryMTX BCT MTX BCTonce BCTreop. BCT-MTX MTX once MTX reop.
Number of patients 8065 4950 1481 164 6583 1287 194 4786 164
Proportion of patients 62 38 50.6 9.9 1.5 36.7 1.3
Median follow-up time 7.3 years 7.0 years 7.3 years 7.5 years 8.7 years 7.0 years 7.0 years
Proportion RT 99.3 30.7 100 100 70.1 30.3 43.3
Year of diagnosis Annual proportion (100 %) Reoperateda Annual proportion (100 %)
BCT MTX
1998 34 % (264) 66 % (512) 16 % 3.3 % 29 % 3.1 % 2.2 % 63.8 % 2.2 %
1999 35 % (279) 65 % (520) 18 % 6.3 % 29 % 3.9 % 2.4 % 61.0 % 4.1 %
2000 41 % (364) 59 % (519) 14 % 3.5 % 35 % 4.0 % 1.8 % 56.7 % 2.0 %
2001 53 % (482) 47 % (422) 21 % 4.3 % 42 % 9.2 % 1.9 % 44.7 % 2.0 %
2002 63 % (736) 37 % (436) 23 % 3.9 % 49 % 11.9 % 2.2 % 35.8 % 1.5 %
2003 72 % (967) 28 % (384) 23 % 3.6 % 55 % 14.9 % 1.6 % 27.4 % 1.0 %
2004 73 % (1005) 26 % (368) 20 % 2.2 % 58 % 13.9 % 1.0 % 26.2 % 0.6 %
2005 72 % (1042) 28 % (407) 17 % 2.7 % 60 % 10.8 % 1.2 % 27.3 % 0.8 %
2006 71 % (962) 29 % (388) 18 % 2.8 % 59 % 11.0 % 1.6 % 27.9 % 0.8 %
2007 68 % (990) 32 % (465) 17 % 1.3 % 57 % 10.5 % 0.9 % 31.5 % 0.4 %
2008 65 % (974) 35 % (529) 14 % 2.1 % 56 % 8.3 % 0.9 % 34.5 % 0.7 %
Age at diagnosis (years)
\30 61 % (31) 39 % (20) 26 % 5.0 % 45 % 16 % 0 % 37 % 2.0 %
30–39 56 % (287) 44 % (222) 26 % 5.0 % 42 % 11 % 3.9 % 41 % 2.2 %
40–49 66 % (1467) 34 % (761) 20 % 4.5 % 53 % 11 % 2.1 % 33 % 1.5 %
50–59 72 % (3024) 29 % (1203) 19 % 3.7 % 58 % 12 % 1.5 % 27 % 1.0 %
60–69 72 % (2515) 29 % (1024) 17 % 2.5 % 59 % 11 % 1.1 % 28 % 0.7 %
70–79 38 % (651) 62 % (1062) 16 % 2.9 % 32 % 5 % 1.3 % 60 % 1.8 %
C80 12 % (90) 88 % (658) 13 % 2.6 % 10 % 1 % 0.5 % 86 % 2.3 %
TNM stage
T1N0 75 % (5165) 25 % (1686) 17 % 2.4 % 63 % 11 % 1.7 % 24 % 0.6 %
T2N0 44 % (888) 56 % (1140) 20 % 2.4 % 35 % 8 % 1.2 % 55 % 1.3 %
T1N1 60 % (1340) 40 % (893) 22 % 4.4 % 47 % 11 % 2.0 % 38 % 1.7 %
T2N1 35 % (672) 65 % (1231) 20 % 4.6 % 28 % 7 % 0.5 % 62 % 3.0 %
Histology
Ductal c. 62 % (6618) 38 % (3981) 18 % 3.5 % 51 % 10 % 1.5 % 36 % 1.3 %
Lobular c. 58 % (756) 42 % (549) 24 % 2.6 % 44 % 12 % 2.0 % 41 % 1.1 %
Other c. 62 % (691) 38 % (420) 19 % 2.6 % 51 % 10 % 1.3 % 37 % 1.0 %
Grade
I 73 % (2261) 27 % (844) 16 % 2.7 % 61 % 11 % 1.1 % 26 % 0.7 %
II 61 % (3600) 39 % (2259) 17 % 3.3 % 51 % 9 % 1.3 % 37 % 1.3 %
III 54 % (1650) 46 % (1382) 23 % 4.1 % 42 % 10 % 2.3 % 44 % 1.8 %
Unknown 54 % (554) 46 % (465) 22 % 2.4 % 42 % 10 % 1.7 % 45 % 1.1 %
BCT once BCT operated once, BCT reop. BCT followed by reoperation, BCT-MTX BCT followed by MTX, MTX once MTX operated once,
MTX reop. MTX with reoperation
a BCT reoperated is calculated by number of primary BCT undergoing BCT reoperation and BCT followed by MTX. MTX reoperated is
calculated by number of primary MTX undergoing MTX with reoperation
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5-year 59.0 13,015 1334 89 % 742 94 %
10-year 59.0 9814 2260 78 % 1083 89 %
Surgical main cohorts
5-year survival BCT 56.9 8065 412 95 % 225 97 %
5-year survival MTX 62.4 4950 922 80 % 517 88 %
10-year survival BCT 56.9 6370 796 86 % 384 93 %
10-year survival MTX 62.4 3444 1464 64 % 699 82 %
Age\ 50 years
5-year survival BCT 43.6 1785 89 95 % 72 96 %
5-year survival MTX 42.7 1003 120 87 % 111 88 %
Age 50–69 years
5-year survival BCT 58.8 5539 232 95 % 115 98 %
5-year survival MTX 59.0 2227 296 86 % 201 90 %
Age C 70 years
5-year survival BCT 74.6 741 91 87 % 38 94 %
5-year survival MTX 78.3 1720 506 69 % 205 86 %
Surgical subcohorts, 5-year survival
BCT operated once 57.0 6583 324 95 % 163 97 %
BCT with reoperation 56.2 1287 67 94 % 48 96 %
BCT followed by MTX 55.2 195 21 89 % 14 92 %
MTX operated once 62.5 4786 884 80 % 484 89 %
MTX with reoperation 59.3 164 38 76 % 33 79 %
FIG. 1 Kaplan–Meier, surgical main cohorts stratified in T1N1M0, grade 3, ductal carcinoma, and age 50–69
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TABLE 3 Crude and adjusted HR on overall and breast cancer death in women with early-stage breast cancer
Crude Adjusted
Overall death Breast cancer death Overall death Breast cancer death
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
Surgical main cohorts
Primary BCT 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Primary MTX 3.11 (2.86–3.38) 3.16 2.79–3.57 1.65 1.50–1.82 1.64 1.43–1.88
Surgical subcohorts
BCT once 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
BCT reop. 1.05 0.87–1.26 1.38 1.07–1.77 1.04 0.86–1.25 1.28 0.99–1.64
BCT-MTX 1.90 1.39–2.58 2.92 1.97–4.33 1.69 1.24–2.31 2.19 1.47–3.26
MTX once 3.90 2.89–3.47 3.35 2.92–3.85 1.68 1.51–1.86 1.72 1.48–2.01
MTX reop. 4.56 3.60–5.78 7.93 5.94–10.58 2.50 1.96–3.19 3.40 2.53–4.58
Year of diagnosis
1998 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1999 0.93 0.79 0.89 0.73
2000 0.87 0.78 0.9 0.77
2001 0.87 0.75 1.05 0.83
2002 0.69 0.53 0.89 0.63
2003 0.77 0.58 0.99 0.76
2004 0.64 0.45 0.89 0.62
2005 0.69 0.34 0.87 0.44
2006 0.6 0.29 0.75 0.39
2007 0.59 0.22 0.77 0.30
2008 0.53 0.17 0.66 0.23
Age categories (years)
\30 2.15 3.12 1.51 1.78
30–39 1.59 2.42 1.15 1.46
40–49 0.98 1.21 0.82 0.91
50–59 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
60–69 1.42 0.96 1.52 1.11
70–79 3.71 2.15 2.98 1.66
C80 8.38 2.92 6.04 2.13
TNM stage
T1N0M0 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
T2N0M0 2.38 2.95 1.41 1.83
T1N1M0 1.56 2.86 1.92 2.18
T2N1M0 3.34 6.57 3.37 3.95
Histology
Ductal c. 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Lobular c. 1.04 0.88 0.93 0.91
Other 1.03 0.89 1.04 1.02
Grade
I 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
II 1.69 2.61 1.41 1.98
III 2.47 5.65 1.92 3.53
Unknown 1.73 2.84 1.30 1.99
Numbers in italic are not significant (p[ 0.05)
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general consensus that MTX and BCT patients have a
similar long-time survival, but corresponds well with the
two studies done in the United States by Whang and
Agarwal, who found better survival in women undergoing
BCT compared with MTX.1–3,5,10,14–16
Possible Selection Effects
The present study is an observational study, and several
possible selection effects might explain the observed dif-
ferences; i.e., the observed differences might be due to
TABLE 4 Crude and adjusted HR on overall and breast cancer death in women with early-stage breast cancer stratified in women\50 years,
women aged 50–69 years, women aged C70 years, and T1N0M0 grade 1
Crude Adjusted
Overall death Breast cancer death Overall death Breast cancer death
HR HR HR HR
Women aged\ 50 years
Surgery Nr
Primary BCT 1785 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Primary MTX 1003 2.10 (1.71–2.59) 2.51 (1.98–3.18) 1.43 (1.15–1.80) 1.58 (1.22–2.04)
Surgical subcohorts
BCT once 1415 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
BCT reop. 304 0.88 (0.57–1.35) 0.84 (0.50–1.41) 0.85 (0.54–1.31) 0.80 (0.48–1.35)
BCT-MTX 66 1.51 (0.79–2.87) 1.50 (0.70–3.23) 1.45 (0.75–2.79) 1.32 (0.60–2.87)
MTX once 957 1.96 (1.56–2.46) 2.32 (1.79–3.01) 1.35 (1.06–1.72) 1.46 (1.11–1.93)
MTX reop. 46 5.42 (3.42–8.61) 6.41 (3.87–10.62) 2.95 (1.83–4.75) 3.12 (1.86–5.25)
Women aged 50–69 years
Surgery type
Primary BCT 5539 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Primary MTX 2227 2.40 (2.12–2.72) 3.26 (2.74–3.88) 1.74 (1.52–2.00) 1.64 (1.35–1.99)
Surgical subcohorts
BCT once 4546 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
BCT reop. 891 1.14 (0.90–1.43) 1.83 (1.34–2.49) 1.09 (0.87–1.39) 1.71 (1.25–2.33)
BCT-MTX 102 2.24 (1.47–3.40) 3.95 (2.32–6.71) 2.03 (1.33–3.09) 2.91 (1.70–6.28)
MTX once 2157 2.42 (2.13–2.78) 3.65 (3.99–4.45) 1.77 (1.35–2.05) 1.85 (1.49–2.30)
MTX reop. 70 5.35 (3.77–7.59) 11.70 (7.77–17.62) 3.32 (2.31–4.78) 4.09 (2.66–6.28)
Women aged C 70 years
Surgery type
Primary BCT 741 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Primary MTX 1720 2.15 (1.84–2.51) 2.23 (1.67–2.96) 1.56 (1.31–1.85) 1.50 (1.10–2.05)
Surgical subcohorts
BCT once 622 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
BCT reop. 92 1.16 (0.77–1.76) 1.05 (0.47–2.32) 1.01 (0.72–1.66) 0.83 (0.34–1.84)
BCT MTX 27 1.42 (0.75–2.69) 2.68 (1.06–6.76) 1.30 (0.68–2.47) 1.92 (0.75–4.90)
MTX once 1672 2.25 (1.89–2.67) 2.36 (1.72–3.23) 1.61 (1.33–1.93) 1.52 (1.08–2.13)
MTX reop. 48 1.67 (1.06–2.64) 2.82 (1.43–5.62) 1.36 (0.85–2.16) 2.14 (1.06–4.31)
T1N0M0 grade 1
Surgery type
Primary BCT 1451 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Primary MTX 366 2.61 (1.91–3.56) 3.52 (1.80–6.90) 1.77 (1.22–2.56) 2.07 (0.94–4.56)
Surgical sub cohorts
BCT once 1245 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
MTX once 358 2.61 (1.88–3.61) 4.73 (2.22–10.10) 1.80 (1.23–2.63) 2.80 (1.18–6.61)
In the T1N0M0 grade 1 strata, 17 primary BCT died and 18 primary MTX died
Numbers in italics are not significant (p[ 0.05)
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other than the surgical procedures. In the following, we
discuss the most probable selection effects that might have
influenced the observed results.
Completeness
The Cancer Registry of Norway during the period
2001–2005 had an overall completeness on cancer esti-
mated at 98.8 %.11 Selection bias due to missing
registration is thus unlikely. There was a higher proportion
of patients undergoing primary MTX without known dis-
tant metastasis status than primary BCT, 65 versus 35 %,
before cohort selection. Nevertheless, information on dis-
tant metastasis status was available for all patients in the
analyzed cohorts; i.e., they were metastasis-free at the time
of diagnosis (M0).
Access to Health Care
Almost every inhabitant in Norway receives the same
health care offer regardless of private insurance, and only
public hospitals provide treatment of breast cancer. This
might be in contrast to the United States, where women
with a higher socioeconomic status are more likely to
undergo BCT.17,18
Comorbidity
Some of the women underwent MTX due to an overall
judgment of their health situation. We have no information
on comorbidity; however, the difference between OS and
BCSS in women younger than aged 50 years was 1 % in
both the primary BCT and primary MTX strata, 3 % for
women undergoing BCT, and 4 % for women undergoing
MTX at age 50–69 years. This indicates that there are
small differences in serious comorbidity in women younger
than age 70 years between the two cohorts. However, co-
morbidity has probably influenced the choice of MTX
among the older women.
Hereditary Breast Cancer
We are not able to stratify for women with hereditary
breast cancer, because BRCA1/2 or prophylactic MTX is
not recorded in the Cancer Registry. However, in a
population-based incidence study in one of the counties
in Norway, it was shown that 2.5 % of the women
studied were mutation carriers.19 This fraction might
have a slight detrimental effect on survival in the MTX
cohort.
Patients Own Choice
In a hospital in Norway, 14 % of the women operated for
breast cancer underwent MTX because of the patient’s own
request, or the cancer had preoperatively been considered
more prevalent than at the final histological examination.20
This might seem like a low proportion. However, a study from
the United States regarding involvement in decision making
about surgery for early-stage breast cancer showed that 9 %
underwent primary MTX based on patient preference.21
Tumor Biology
When surgery is decided, results from cytology or
biopsy together with mammogram and ultrasound normally
give information on morphology, grade, and tumor size.
Details on tumor biology, such as lymph vascular invasion,
are normally not known when the decision on type of
surgery is made, and therefore do not explain the difference
between BCT and MTX. Furthermore, routine examination
on HER2 was recommended from June 2005, late in the
study period; therefore, triple-negative disease cannot ex-
plain the difference in survival between BCT and MTX.
Radiation Therapy
Today’s guidelines from NBCG differ from the guide-
lines in our study period, and today fewer patients would
receive RT based on axillary node positive disease (1–3
lymph nodes). MTX with RT and MTX without RT are not
directly comparable in our study, based on different rec-
ommendations for RT during the study period, but RT
given to women with node-positive disease does not seem
to increase the survival benefit of the MTX cohort.
Women undergoing MTX with RT likely represent a
high-risk disease. Multivariate analysis where none of the
patients in the MTX group received RT showed the benefit of
BCT compared with MTX (HR 1.51; 95 % CI 1.27–1.80).
Adjuvant Therapy
The Cancer Registry is incomplete when it comes to
chemotherapy and antiestrogen therapy given. However,
recommendations for chemo and antiestrogen therapy are
identical for patients undergoing BCT and MTX. In this
study it was not possible to see whether women undergoing
MTX have less compliance to recommended therapy.
Sensitivity Analysis of Misclassification, Selection Bias,
and Unmeasured Confounder
Sensitivity analyses were done under several different
assumptions within the following three areas:
Breast-Conserving Therapy and Mastectomy 3843
misclassification of surgery; selection bias, and unmea-
sured confounder. However, the larger the difference in the
proportion of unmeasured confounding in the two cohorts,
the lesser the rate ratio adjusted for unmeasured con-
founding. In the present study, first when assuming that as
much as 90 % of women undergoing MTX had uncon-
trolled confounding (e.g., compliance to adjuvant therapy),
and only 10 % in the BCT cohort, did we find a rate ratio of
1.0. We find it unlikely that the difference in adjuvant
therapy was more than 10–30 % between the surgical
groups (both surgical groups have the same recommenda-
tions to adjuvant therapy), and thus the adjusted rate ratio
for unmeasured confounding was found to be 1.78, when
assuming 10 and 40 % unmeasured confounding in BCT
and MTX, respectively, compared with an unadjusted rate
ratio of 3.31.
Proportion of Women Undergoing BCT Compared
with MTX Changed During Study Period
The proportion of BCT at the beginning of study period
was lower than at the end of study period, but the benefit of
BCT compared with MTX did not seem to change during
the study period.
Strengths and Weaknesses of the Study
The major strength of our study is that the results are
based on the whole population of women diagnosed with
early-stage breast cancer in Norway during the period
January 1, 1998 to December 31, 2008. Dividing the sur-
gical main cohort into five surgical subcohorts made it
possible to include women initially treated with BCT fol-
lowed by MTX without receiving RT. If this had not been
done, women initially treated with BCT would have been
regarded as BCT without RT and excluded from the cohort.
The weaknesses are that the Cancer Registry lacks in-
formation on hormone receptor status and information on
given adjuvant therapy. However, neither of these factors
determines whether a patient should undergo BCT or
MTX.7 Observational studies, such as this, are prone to
selection effects. However, as discussed above, we find it
unlikely that this can explain all of the observed differences
in survival among women undergoing BCT compared with
MTX.
CONCLUSIONS
This study corroborates the findings of two studies from
the United States showing better survival for women un-
dergoing BCT compared with MTX. This advantage could
not be attributed to differences in tumor biology. Further
studies are necessary to determine whether this benefit is
caused by variation in adjuvant therapy or by type of
surgery.
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